Okay, here's a breakdown of⁤ the provided text, ⁤focusing on key details and summarizing the study described.

Main Topic: A new study identifying a potential biomarker for ⁢kidney disease progression - a specific type of⁢ immune cell (CD45 + C1q + CCR8+ cells).

Key Points:

* Problem: Predicting which patients with Chronic Kidney Disease (CKD) will experience rapid decline in kidney ⁢function is challenging.

* Focus: The study investigates the role of⁣ fibrosis (tissue scarring) in both CKD ⁢and Acute kidney Injury (AKI) and seeks early cellular indicators of this process.

* The Biomarker: Researchers identified a ⁣population of mononuclear immune cells expressing C1q and CCR8 (CD45 + C1q + CCR8+ cells)⁤ as potentially pro-fibrotic.

* Study Design:

* Compared blood⁤ samples⁣ from 44 patients with kidney disease to healthy⁣ volunteers using multicolor flow cytometry.

* analyzed correlations between the percentage ⁣of these cells and clinical ⁢parameters (serum ⁤creatinine, eGFR, hemoglobin, urinary protein).

* ⁣ ⁤ Findings:

* Kidney disease patients had significantly higher levels of CD45 + C1q + CCR8+ cells than healthy ⁢controls (3.7% vs 1.5%).

* Levels were highest ⁣in AKI.

* ⁣ ⁢The percentage of these cells correlated positively with serum creatinine and urinary protein levels (indicators of kidney dysfunction).

* ⁤ Significance: This suggests that these cells could⁤ serve as a biomarker to identify patients at risk of kidney function decline.

* Context: CKD is noted as the third fastest growing⁣ cause of death globally.

In essence,⁤ the study suggests that ⁢measuring these specific immune ⁣cells in a blood sample could help doctors identify patients with kidney disease who are likely to worsen, potentially allowing ⁤for earlier intervention.

Let me know if you'd ⁣like ⁣me to elaborate on any specific aspect⁤ of the text!